menu
    • menu
    [{"orgOrder":0,"company":"GPCR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"GPCR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GPCR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GPCR Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GPCR Therapeutics","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"GPCR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GPCR Therapeutics \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"GPCR Therapeutics \/ Bridge Biotherapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by GPCR Therapeutics

    Menu

    GPCR Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GPCR Therapeutics

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed

                            GPCR Therapeutics

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Bridge Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            GPCR Therapeutics Announces Out-Licensing Agreement with Bridge Biotherapeutics in Idiopathic Pulmonary Fibros...

                            Details : Bridge Biotherapeutics and GPCR will pursue joint development and commercialization of the CXCR4-LPA1 inhibitor combination therapy and conducting a multinational phase 2a clinical trial of BBT-877, an autotaxin inhibitor for the treatment of idiopathic ...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : $1.5 million

                            December 14, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Bridge Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GPCR Therapeutics

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed

                            GPCR Therapeutics

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GPCR Therapeutics Expands Pipeline into Fibrosis with a Combination Approach Targeting LPA1

                            Details : The company work on unique approach to inhibit two signaling receptors, lysophosphatidic acid receptor 1 (LPA1) and CXCR4, for the effective treatment of Idiopathic Pulmonary Fibrosis (IPF).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 10, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth